Convalescent plasma therapy in patients with COVID-19

Tuğçe Nur Yiğenoğlu, Tuba Hacıbekiroğlu, İlhami Berber, Mehmet Sinan Dal, Abdülkadir Baştürk, Sinem Namdaroğlu, Serdal Korkmaz, Turgay Ulas, Tuba Dal, Mehmet Ali Erkurt, Burhan Turgut, Fevzi Altuntaş, Tuğçe Nur Yiğenoğlu, Tuba Hacıbekiroğlu, İlhami Berber, Mehmet Sinan Dal, Abdülkadir Baştürk, Sinem Namdaroğlu, Serdal Korkmaz, Turgay Ulas, Tuba Dal, Mehmet Ali Erkurt, Burhan Turgut, Fevzi Altuntaş

Abstract

There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID-19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID-19. CP may be an adjunctive treatment option to the anti-viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200-600 mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID-19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.

Keywords: COVID-19; SARS CoV-2; convalescent plasma.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

© 2020 Wiley Periodicals, Inc.

References

    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, ofNovel coronavirus‐infected pneumonia. N Engl J Med. 2020;382:1199‐1207.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumoniain China, 2019. N Engl J Med. 2020;382:727‐733.
    1. World Health Organization Press Conference . The World Health Organization (WHO) has officially named the disease caused by the novel coronavirus as COVID‐19. . Accessed on April 17, 2020.
    1. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome‐related coronavirus: the species and its viruses ‐ a statement of the Coronavirus Study Group. bioRxiv. 2020. 10.1101/2020.02.07.937862.
    1. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid‐19 in China: a nationwide analysis. Eur Respir J. 2020;55:2000547. 10.1183/13993003.00547-2020.
    1. Graham BS, Ambrosino DM. History of passive antibody administration forprevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015;10:129‐134.
    1. Bloch EM, Shoham S, Casadevall A, et al. Deployment ofconvalescent plasma for the prevention and treatment of COVID‐19. J Clin Invest. 2020;130:2757‐2765. 10.1172/JCI138745.
    1. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuinghigh‐dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676‐678.
    1. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severeacute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919‐922.
    1. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44‐46.
    1. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374:33‐42.
    1. Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirusinfection: a single centre experience. Antivir Ther. 2018;23:617‐622.
    1. Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS‐CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22:1554‐1561.
    1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID‐19 with convalescent plasma. Jama. 2020. Mar 27;323:1582. 10.1001/jama.2020.4783.
    1. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasmatherapy in severe COVID‐19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–9496. 10.1073/pnas.2004168117.
    1. FDA . Investigational covid‐19 convalescent plasma—emergency INDs. . Accessed May 11, 2020.
    1. Turkish Ministry of Health . . Accessed April 17, 2020.
    1. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc‐mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548.
    1. Gunn BM, Yu WH, Karim MM, et al. A role for fc function in therapeutic monoclonal antibody‐mediated protection against Ebola virus. Cell Host Microbe. 2018;24:221‐233.
    1. Ozma MA, Maroufi P, Khodadadi E, et al. Clinical manifestation, diagnosis, prevention and control of SARS‐CoV‐2 (COVID‐19) during the outbreak period. Infez Med. 2020;28:153‐165.
    1. Amanat F, Nguyen T, Chromikova V, et al. A serological assay to detect SARS‐CoV‐2 seroconversion in humans. medRxiv. 10.1101/2020.03.17.20037713.
    1. Okba NMA, Muller MA, Li W, et al. SARS‐CoV‐2 specific antibody responses in COVID‐19 patients. medRxiv. 2020. 10.1101/2020.03.18.20038059.
    1. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis. J Med Virol. 2020. 10.1002/jmv.25727.
    1. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID‐19). Clin Infect Dis. 2020. pii: ciaa310. 10.1093/cid/ciaa310.
    1. Duan K, Liu B, Li C, et al. The Feasibility of Convalescent Plasma Therapy in Severe COVID‐19 Patientss:a Pilot Study. medRxiv. 2020. 10.1101/2020.03.16.20036145.
    1. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS‐CoV‐2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020. 10.1093/cid/ciaa344.
    1. Casadevall A, Scharff MD. Return to the past: the case for antibody‐basedtherapies in infectious diseases. Clin Infect Dis. 1995;21:150‐161.
    1. Casadevall A. Passive antibody administration (immediate immunity) as aspecific defense against biological weapons. Emerg Infect Dis. 2002;8:833‐841.
    1. . Accessed May 11, 2020.
    1. Casadevall A, Pirofski LA. Antibody‐mediated regulation of cellular immunityand the inflammatory response. Trends Immunol. 2003;24:474‐478.
    1. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994;38:1695‐1702.
    1. Rijnders B. Convalescent plasma as therapy for Covid‐19 severe SARS‐CoV‐2 disease (CONCOVID study) (ConCoVid‐19). Identifier: NCT04342182
    1. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108:759‐769.
    1. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion‐transmittedinfections. Blood. 2019;133:1854‐1864.
    1. AABB . Standards for blood banks and transfusion services. AABB: Bethesda, MD; 2018.
    1. FDA . Electronic Code of Federal Regulations: 630.30 Donation suitability requirements. . Updated March 17, 2020. Accessed March 19, 2020.
    1. Wang W, Xu Y, Gao R, et al. Detection of SARS‐CoV‐2 in different types of clinical specimens. Jama. 2020;323(18):1843 10.1001/jama.2020.3786.
    1. Chang L, Zhao L, Gong H, Wang L, Wang L. Severe acute respiratory SyndromeCoronavirus 2 RNA detected in blood donations. Emerg Infect Dis. 2020;26(7):1631–1633. 10.3201/eid2607.200839.
    1. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody‐dependent enhancement of severe dengue disease in humans. Science. 2017;358:929‐932.
    1. Tetro JA. Is COVID‐19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22:72‐73.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner